DXCM

As of 2026-10-26, DXCM scores 52out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. DXCM trades at $78.57, 8% above the band ceiling.

DXCM scores 52 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 52. Its strongest factor is value at 66 (strong), where it screens cheap on the model's valuation inputs, followed by quality at 57. The weakest is volume at 45, where volume gives little confirmation. Among Healthcare stocks it ranks in roughly the top 40% of the Healthcare names the model scores.

On valuation, DXCM is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 53. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on DXCM, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where DXCM sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for DXCM runs $47.51–$72.44. Current price $78.57 sits 8% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.